Remedy Raises Series A Funding Led by L Catterton

Remedy Science (Remedy), the dermatologist-developed, education-first skincare brand, announced the closing of its Series A funding round led by L Catterton, with participation from existing investor Norwest and new investor Sonoma Brands Capital.

Founded by board-certified dermatologist Dr. Muneeb Shah, Remedy’s portfolio addresses the concerns dermatologists see every day, including dark spots, dryness, fine lines, dullness, keratosis pilaris, and sensitive skin.

The Series A investment will support Remedy’s next phase of growth, including advancing clinical research, expanding its pipeline of dermatologist-developed products, building a best-in-class team and improving inventory depth to meet increasing demand across DTC, Amazon, and Target. 

Remedy also plans to deepen its capabilities across formulation, testing, and consumer education as it continues building a scaled dermo-cosmetic platform. 

Dr. Muneeb Shah, founder and CEO of Remedy, said,

“For years, I saw patients who were doing everything right but still struggling to find products that delivered meaningful results without irritation or unnecessary complexity. Remedy was created to modernize dermatologist-developed skincare. Each formula starts with a real patient need. We then innovate with the latest ingredient technologies to create clinically tested, high-efficacy formulas with a focus on visible results and safety for sensitive skin.”

Norwest, which led Remedy’s seed round, is also deepening its commitment to the company through participation in the Series A.

The partnership with L Catterton also brings significant beauty category experience to Remedy as the brand continues to scale.